Log in to search using one of your social media accounts:

 

FDA has approved biosimilar of Roche's Avastin
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.09/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 15, 2017 Category: Urology & Nephrology Source Type: news

Department of Defense Kidney Cancer Research Program
The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).09/30...
Source: Kidney Cancer Association - September 14, 2017 Category: Urology & Nephrology Source Type: news

Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news

Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.09/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news

Kidney Cancer Guidelines
NCCN's Caitlyn Donnelly (left), Katy Winckworth-Prejsnar (center), and KCA's Paula Bowen (right) display Kidney Cancer Patient Guidelines® in French and German at the 2017 ESMO meeting in Madrid. Chinese and English translations are also available both online and in hardcopy from NCCN and KCA.09/12/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news

Bristol's drug cocktail cuts kidney cancer death risk 37 percent
MADRID (Reuters) - A combination of two Bristol-Myers Squibb immunotherapy drugs cut the risk of death by 37 percent in a key group of kidney cancer patients, data from a closely watched clinical trial showed on Sunday. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

ARMO BioSciences's Phase 1b Trials Demonstrate Continued Promising Response Rates and Survival
It is particularly promising to see these high, durable responses in advanced NSCLC patients with low as well as high PD-L1 expression and in intermediate to poor risk advanced RCC patients who have received 2 or more prior therapies."09/11/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 10, 2017 Category: Urology & Nephrology Source Type: news

BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers stops kidney cancer drug test after early success
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers stop kidney cancer drug tests after early success
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial well ahead of schedule, despite earlier reporting mixed results on other main goals. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers kidney cancer drug meets early success, study stopped
(Reuters) - Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients helped it end the trial early, despite having reported mixed results on other main goals earlier. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol-Myers kidney cancer drug meets main goal of late-stage trial
(Reuters) - Bristol-Myers Squibb Co said on Thursday its combination therapy of its two top drugs to treat a type of kidney cancer met one of the main goals of a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - September 7, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Kidney cancer symptoms: Seven signs YOU could be suffering with the disease
KIDNEY cancer is one of the most common types of cancer in the UK - usually affect people in their 60s and 70s. (Source: Daily Express - Health)
Source: Daily Express - Health - September 1, 2017 Category: Consumer Health News Source Type: news

European Commission licences EUSA ’s advanced RCC treatment fotivda
Jazz Pharmaceuticals subsidiary EUSA Pharma ’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 30, 2017 Category: Pharmaceuticals Source Type: news

Translocation Renal Cell Carcinoma: An Update
Microphthalmia-associated transcription (MiT) family translocation renal cell carcinoma (tRCC) comprises Xp11 tRCC and t(6;11) RCC.08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Advice For Newly Diagnosed Patients From Mike Lawing
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world ’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.08/26/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

AVEO Pharma stock rises 6% after cancer drug gets approved
The drug, Fotivda, was approved for adults with advanced renal cell carcinoma -- the most common type of kidney cancer08/29/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 29, 2017 Category: Urology & Nephrology Source Type: news

Cancer drug turns BLACK cancer patient WHITE due to side effect
(Natural News) Can a drug for cancer be racist? That might be the rallying call of “antifa” terrorists, should they find out about what’s happening to Paula Edwards, a 54-year-old black woman from Loughborough in England. Edwards has reportedly been taking a drug for terminal kidney cancer known as Votrient (pazopanib), manufactured by Novartis, that... (Source: NaturalNews.com)
Source: NaturalNews.com - August 28, 2017 Category: Consumer Health News Source Type: news

OncoBreak: Bad News via Microscope; Risky B Vitamins; End of Kidney Cancer Trend?
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 24, 2017 Category: American Health Source Type: news

Longer Telomeres Linked to Renal-cell Carcinoma Risk Longer Telomeres Linked to Renal-cell Carcinoma Risk
Genetic variants that predispose individuals to longer telomere length appear to be associated with an increased risk of renal-cell carcinoma (RCC), according to results from a genome-wide association studies (GWAS) database analysis.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 22, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Kidney Cancer Renal Pelvis and Ureter
Kidney Cancer: Renal Pelvis and Ureter (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - August 22, 2017 Category: General Medicine Source Type: news

Geriatric Consults Remain Rare in Kidney Cancer Care
Although use of medical co - management and rehabilitation services increasing (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 21, 2017 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Nephrology, Nursing, Oncology, Radiology, Surgery, Urology, Journal, Source Type: news

Exelixis Submits sNDA for Kidney Cancer Drug
The sNDA submission was based on positive results from phase II trial, CABOSUN, in patients with previously untreated advanced RCC with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).08/20/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

California kidney cancer shows declining incidence
The research study, published online in the peer-reviewed journal Kidney Cancer, is important because it is the first report to demonstrate that the rising rate of kidney cancer seen in the U.S. over the past two decades may have ended.08/19/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 19, 2017 Category: Urology & Nephrology Source Type: news

'Junk food' may increase cancer risk in 'healthy weight' women
"Women who eat junk food such as burgers or pizza are increasing their risk of cancer even if they're not overweight, new research has warned," reports the Daily Mail. The story is based on research from the US looking at the diet of postmenopausal women in the 1990s and then tracking the development of a variety of cancers over about 15 years. "Junk food" is often defined as food that is rich in calories (energy dense food) but low in nutrients. Having a diet high in energy dense foods, such as biscuits, chocolate and pizza was found to increase the risk of cancer in these women, specifically in those ...
Source: NHS News Feed - August 18, 2017 Category: Consumer Health News Tags: Cancer Source Type: news

Black cancer patient slowly turning white because of drug
Paula Edwards, 54, from Loughborough, was diagnosed with terminal kidney cancer in 2012 and was initially given 12 months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2017 Category: Consumer Health News Source Type: news

Black cancer patient is slowly turning white
Paula Edwards, 54, from Loughborough, was diagnosed with terminal kidney cancer in 2012 and was initially given 12 months to live. (Source: the Mail online | Health)
Source: the Mail online | Health - August 18, 2017 Category: Consumer Health News Source Type: news

Study of California kidney cancer shows declining incidence, end of a trend
(University of California - Davis Health System) Study of kidney cancer incidence in California over 25 years is the first report to demonstrate that the rising rate of kidney cancer seen in the US over the past two decades may have ended. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 18, 2017 Category: Cancer & Oncology Source Type: news

Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news

BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Advice For Newly Diagnosed Patients From Our Director Mike Lawing
Michael B. Lawing from Rutherford County, NC is involved in advocacy for cancer patients at the local, National and International levels. He serves as a Member of the Board of Directors of the Kidney Cancer Association, the world ’s largest non-profit dealing exclusively with Kidney Cancer with over 90,000 members in 102 countries.08/26/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news

Patent for Enhancing Immunotherapy in Cancer Treatment Granted
This patent provides intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs08/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news

NICE knocks back advanced kidney cancer drug duo
While the guidance is only in its draft stage, the decision could mean that Eisai ’s Kisplyx (lenvatinib) and Eusa Pharma’s Fotivda (tivozanib) are withheld from NHS patients in England and Wales.08/15/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 15, 2017 Category: Urology & Nephrology Source Type: news

Bristol-Myers Squibb announces topline results from CheckMate -214
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (Source: World Pharma News)
Source: World Pharma News - August 15, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Positive Surgical Margins in RCC More Common Among African Americans
African American patients with localized renal cell carcinoma who underwent robotic partial nephrectomy were at an increased risk for positive surgical margins compared with white patients. (Source: CancerNetwork)
Source: CancerNetwork - August 14, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Multigene Panel Tests Can ID Hereditary Kidney Cancer
Most commonly altered genes were folliculin and fumarate hydratase, altered in 1.8 and 1.3 percent (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 12, 2017 Category: Cancer & Oncology Tags: Nephrology, Oncology, Journal, Source Type: news

Improved analysis of kidney cancer
(Lund University) Researchers compare the gene expression in tumor cells from a kidney cancer patient with cells from healthy tissue to figure out in which part of the kidney the cancer began and what went wrong in these cells. A research team at Swedish Lund University has discovered that in the Cancer Genome Atlas database, the gene expression in reference samples from normal tissue varies, depending on where in the kidney the samples have been taken. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 11, 2017 Category: International Medicine & Public Health Source Type: news

Immunicum starts enrolment in US for Phase II oncology trial
Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma. (Source: Drug Development Technology)
Source: Drug Development Technology - August 10, 2017 Category: Pharmaceuticals Source Type: news

Calithera begins Phase II trial of CB-839 to treat renal cell carcinoma
Pharmaceutical firm Calithera Biosciences has begun a Phase II clinical trial of CB-839 in combination with Afinitor (everolimus) ‎ for the treatment of patients with renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 7, 2017 Category: Pharmaceuticals Source Type: news

Dr. Choueiri Discusses Novel RCC Drug Combos
In an interview with OncLive during ASCO, the study ’s lead author, Toni Choueiri, MD, senior physician and director of the Kidney Cancer Center at Dana-Farber Cancer Institute, reflected on the avelumab/axitinib results and other emerging combos in RCC.08/07/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 5, 2017 Category: Urology & Nephrology Source Type: news

Second-Line Therapy Options in Metastatic Renal Cell Carcinoma
This video reviews the various treatment options for metastatic renal cell carcinoma in the second-line setting, including considerations for different toxicity profiles. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

First-Line Treatment of Metastatic Renal Cell Carcinoma
This video reviews the first-line treatment of metastatic renal cell carcinoma, including for those patients who are ineligible for interleukin-2. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2017 Category: Cancer & Oncology Authors: Neeraj Agarwal, MD Tags: Renal Cell Carcinoma Videos Genitourinary Cancers Source Type: news

New lung and kidney cancer drug added to PBS in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2017 Category: Drugs & Pharmacology Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC). (Source: World Pharma News)
Source: World Pharma News - July 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Give chronic kidney disease patients a statin, doctors urged
20 mg of atorvastatin will help curb their risk of cardiovascular disease, says NICE Related items fromOnMedica Taking statins linked to improved heart structure and function Statins' side effects have been overstated, study suggests Salt intake linked to CVD risk in kidney patients Diet for lowering blood pressure also reduces risk of kidney disease Kidney cancer drug approved for NHS use (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 27, 2017 Category: UK Health Source Type: news

Drug combination more effective in metastatic renal cell cancer
Researchers report they have identified new drug combination is more effective and better tolerated in the treatment of metastatic renal cell cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - July 26, 2017 Category: Consumer Health News Source Type: news

Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - July 26, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
(Dartmouth-Hitchcock Medical Center) A novel combination of nivolumab plus ipilimumab for patients with metastatic kidney cancer is proving to be a more effective treatment with more durable tumor response than the two immunotherapies used separately. The promising combination therapy demonstrated manageable safety, notable antitumor activity, and durable responses with better long term overall survival in patients with metastatic renal cell cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news

New Journal, Kidney Cancer, Launched With Expert Editorial Board
Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the kidney.07/21/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 21, 2017 Category: Urology & Nephrology Source Type: news

Exelixis Announces Settlement of Dispute with Genentech Regarding Companies ’ Collaboration
Effective July 1, 2017, as part of the settlement the companies entered into an amendment (the “Amendment”) to the existing Collaboration Agreement, dated December 22, 2006, to revise the revenue and cost-sharing arrangements for the collaboration. The Amendment resolves the companies’ dispute pursuant to the arbitration demand filed on June 3, 2016, and aligns both companies’ interes ts in advancing cobimetinib as a promising therapy for patients with multiple forms of cancer.07/21/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - July 21, 2017 Category: Urology & Nephrology Source Type: news